Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 déc. 2019 08h00 HE | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces PV-10® Abstract Accepted for Presentation at Society of Interventional Radiology (SIR) 2020 Annual Scientific Meeting

KNOXVILLE, TN, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting cancer immunotherapy PV-10 (rose bengal...
21 nov. 2019 10h19 HE | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces Presentation of Initial Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Refractory Advanced Melanoma at SMR 2019 Congress

First 10 checkpoint-refractory melanoma patients treatedEstablished safety profiles of PV-10 and KEYTRUDA were maintained20% ORR and 40% DCR (RECIST 1.1)Changes in immune system activation biomarkers...
21 nov. 2019 09h00 HE | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces Presentation of Updated Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Naïve Advanced Melanoma at SMR 2019 Congress

Full accrual of 21 checkpoint-naïve melanoma patientsNo safety concerns identified; no significant overlap of toxicities95% 12-month OS rate; 100% 12-month DSS rate; Median PFS of 11.7 months10% CR...
24 oct. 2019 07h00 HE | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces Acceptance of PV-10® Poster Presentations at ESMO Immuno-Oncology Congress 2019

KNOXVILLE, TN, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting, cancer immunotherapy PV-10 (rose bengal...
24 sept. 2019 09h00 HE | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces Acceptance of PV-10 Poster Presentations at SMR 2019 Congress

KNOXVILLE, TN, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting cancer immunotherapy PV-10® in combination...
12 sept. 2019 09h00 HE | Source: Luminate

Luminate NY Adds Two to Its World-Class Advisory Board

Optics, Photonics, and Imaging Accelerator Welcomes Jenifer Bunis and Linda Smith ROCHESTER, N.Y., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Luminate NY, the world’s only business accelerator for...
29 août 2019 08h07 HE | Source: Copeland Biosciences Corp.

Copeland Biosciences Corp. Secures Exclusive Canadian Distribution Rights for CareWear® Wearable Light Therapeutics Systems

TORONTO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Copeland Biosciences Corp, an orthopedic treatment company that provides remedies to relieve inflammatory pain with proprietary pharmaceutical and...
27 août 2019 09h00 HE | Source: Provectus Biopharmaceuticals Inc.

PV-10-based Cancer Combination Therapy Clinical Trial Design Wins Australasian Gastro-Intestinal Trials Group’s New Concepts Award

Two-stage, 34-patient, Phase 2 study combines PV-10 and Keytruda® (pembrolizumab) for treatment of metastatic neuroendocrine tumorsCombination powered for 19% ORR vs 3.7% ORR for Keytruda...
15 juil. 2019 08h00 HE | Source: Provectus Biopharmaceuticals Inc.

Provectus Receives Notice of Allowance for Fourth Cancer Combination Therapy Patent from the United States Patent and Trademark Office

- Further patent protection of combinations of intratumoral PV-10 and checkpoint inhibitor (CI) drugs for the treatment of multiple, different, solid tumor cancers KNOXVILLE, TN, July 15, 2019 ...
11 juil. 2019 15h31 HE | Source: International Photodynamic Association

Girgis Obaid and Srivallessha Mallidi Received 2019 Early Investigator Awards at the 17th World Congress of the International Photodynamic Association

Boston, USA, July 11, 2019 (GLOBE NEWSWIRE) -- At the 17th International Photodynamic Association World Congress in Boston, Massachusetts, Dr. Girgis Obaid and Dr. Srivalleesha Mallidi were...

Page précédente